The 23

Nuroflux

Illuminating clinical blind spots

RapidAim logo

Founders

Dr David Cardoso CBO

Sam Van Bohemen CEO & CTO

Get in Contact

nuroflux.com

T: 0435 045 054

Nuroflux is developing an innovative wearable medical device for the continuous monitoring of stroke patients.
Co-founder Sam has an honours degree in neuroscience and is doing a PhD in Biomedical Engineering. Co-founder Dr David Cardoso has a PhD in Medicine and is doing an MBA. They are supported by a strong team of advisors with experience in medtech commercialisation, clinical care of patients, IP, regulatory affairs, and market access. Nuroflux is pre-revenue and currently getting ready for a clinical safety study which will be followed by product development and more clinical trials.

What (and whose) problem is your company trying to solve?

CT scans are used to diagnose stroke. They provide imaging snapshots and due to radiation exposure are only performed every 24 hours. In the first 24 hours, patients will receive treatment and are at risk of having a secondary stroke. However, there is currently no way to continuously monitor cerebral blood flow (CBF) and brain activity, which are key indicators in stroke. Standard care relies upon follow up CT scans and nurses talking to patients, which is subjective.

We are developing a wearable device that utilises a proprietary multi-modal system to provide continuous monitoring of CBF and brain activity. This will enable treatment monitoring and the detection of secondary strokes. Leading to faster detection, intervention and improved patient outcome. This will also reduce the number of CT scans required.

placeholder

Sam Van Bohemen

Co-founder, CEO & CTO, Nuroflux

Sam Van Bohemen has a first-class neuroscience honours degree with a minor in pharmacology from The University of Otago. He used electroencephalography (EEG) to classify subtypes of attention deficit hyperactive disorder in children. Sam moved to Sydney to pursue a career in biomedical engineering. He is currently doing a PhD at The University of Sydney, where he has developed a new method for monitoring changes in cerebral blood flow. Sam founded Nuroflux in September 2020.
tech 23 dots

Would you like to call out a mentor who has helped your company? Tell us a little about them.

Dr Philip Boughton, one of my PhD supervisors has been instrumental in the creation of nuroflux. Philip has been active in the medtech industry for over 20 years. He has a passion for developing innovative healthcare solutions. I am very grateful for Philip’s continued support as nuroflux continues to grow.

Check out the rest of The 23…